Alice Tsang Shaw, Ph.D., M.D.
Co-Author
This page shows the publications co-authored by Alice Shaw and Michael Lawrence.
Connection Strength
0.621
-
Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. NPJ Precis Oncol. 2020; 4:21.
Score: 0.222
-
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018 06; 8(6):714-729.
Score: 0.189
-
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clin Cancer Res. 2021 05 15; 27(10):2899-2909.
Score: 0.058
-
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clin Cancer Res. 2020 06 01; 26(11):2535-2545.
Score: 0.054
-
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019 10; 9(10):1372-1387.
Score: 0.052
-
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nat Med. 2018 05; 24(4):512-517.
Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.